Sage fo­cus­es on suc­cess­ful launch of post­par­tum de­pres­sion drug

Sage Ther­a­peu­tics is dou­bling down on the “block­buster po­ten­tial” of its post­par­tum de­pres­sion drug Zurzu­vae, ex­pand­ing pro­fes­sion­al pro­mo­tions and tak­ing steps to­ward a di­rect-to-con­sumer launch af­ter a se­ries of dis­ap­point­ments.

It’s al­ready scaled up in-per­son and non-per­son­al pro­mo­tions to OB-GY­Ns, pri­ma­ry care physi­cians and psy­chi­a­trists who are al­ready writ­ing scripts, and re­cent­ly launched the Zurzu­vae PPD con­sumer web­site, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER